The issuer's primary schedule, accessed on September 21, 2021, at https://www.ssga.com/library-content/products/fund-data/etfs/us/distribution/SPDR_Dividend_Distribution_Schedule.pdf, shows that all 11 sector ETFs have an ex-date of September 21 and a pay date of September 23. The glossary explains that shares bought on the ex-date do not include the latest distribution entitlement, meaning they do not receive the latest dividend payout. Since the sector rotation own ledger is empty and a planned purchase is set for Monday during regular trading hours, the September dividend should not be added to the expected proceeds of the new Monday lots. The historical adjusted momentum remains required. The provider's raw and all close differences for XLK, XLE, and XLV are 0.22, 0.38, and 0.64, respectively, which are observed adjustment differences, but not independently confirmed payouts. A workbook from https://www.ssga.com/library-content/products/fund-data/etfs/us/spdr-etf-historical-distributions.xlsx was downloaded and parsed, but no September amounts were established. Other funds might have older entitled shares, but their trade dates and cash receipts cannot be used. The distribution reduces fund assets when paid, and entitlement and market repricing must be separated from trading alpha. The source is the issuer, which is interested but closest to the calendar, while the provider is independent of the issuer for historical bars, but not for independent confirmation of cash. There is no valuation or news override, and no dividend-capture trade will be made.
The analysis is based on two premises. First, snapshots from September 17, accessed on September 21, show the following forecast multiples for certain funds: XLK has a price-to-earnings ratio of 26.17, a price-to-cash-flow ratio of 28.60, and a growth estimate of 36.25%, XLE has a price-to-earnings ratio of 12.46, a price-to-cash-flow ratio of 8.77, and a growth estimate of 10.87%, and XLV has a price-to-earnings ratio of 20.04, a price-to-cash-flow ratio of 17.71, and a growth estimate of 11.77%. These ratios are sensitive to forecasts, not actual earnings outcomes. Second, the fixed rotation strategy does not allow for valuation veto, meaning that investments are not rejected based on their valuation. The sources of this information are the State Street website pages for the XLK, XLE, and XLV funds. The XLV fund has 60 holdings, compared to 59 in the index, which explains the prior difference of 1 as a difference in index count, not an error in the data. However, there are counterexamples, such as high forecast growth for XLK that can still disappoint, a low price-to-earnings ratio for XLE that can reflect peak earnings, and defensive XLV that can still decline. The provider of the funds benefits from assets and fees, and the snapshots describe its products but are not corroborated profit forecasts. The conclusion is to retain measured signals, track stops rather than invent cheaper substitutes, as no new fundamental change was found.
The premises of this review are: 1) our ledger has no current holdings, so we are reviewing potential investments in XLK, XLE, and XLV, focusing on XLK and not the current trend of XLE. 2) As of September 17, accessed on September 21, the financial snapshots of these investments are: XLK has a price-to-earnings ratio of 26.17, a price-to-cash flow ratio of 28.60, and an estimated growth rate of 36.25%; XLE has a price-to-earnings ratio of 12.46, a price-to-cash flow ratio of 8.77, and an estimated growth rate of 10.87%; XLV has a price-to-earnings ratio of 20.04, a price-to-cash flow ratio of 17.71, and an estimated growth rate of 11.77%. These numbers come from the State Street website, which provides information on the Technology Select Sector SPDR ETF (XLK), the Energy Select Sector SPDR ETF (XLE), and the Health Care Select Sector SPDR ETF (XLV). 3) Forward earnings are estimates and do not necessarily predict when events will happen. The biggest concerns for XLK are that its high expected growth may not happen, which could lower its value, but if cash growth continues, it could support its current price. For XLE, the concern is that its low forward multiple could be a trap if energy prices fall or costs rise, but if there is a shortage of energy, it could do well. For XLV, the concern is that its lower expected growth and high forward multiple may not protect it from disappointing earnings, but if people keep paying for healthcare, it could do well. The people who already own these investments and the fund issuer, who earns fees no matter what, would benefit if the investments do well. We did not find any new information about the companies' cash flow tonight, so we are not changing our investment plan. We will keep our current selection and only sell based on evidence. We are not considering individual company names, cryptocurrency, or non-US investments. Our analysis is limited by the estimates and the timing of the snapshots, so we are aware of the risks, but we are not changing our investments based on discretion.
The premises are as follows: 1) The primary issuer pages for XLK, XLE, and XLV were read on September 20 at 02UTC, with snapshots from September 17 that do not reflect new earnings. 2) The XLK issuer benchmark describes 11 sectors that collectively cover the S&P 500, which means broad sector coverage, but not every US listing or global equity. The source for this information is https://www.ssga.com/us/en/individual/etfs/state-street-technology-select-sector-spdr-etf-xlk, https://www.ssga.com/us/en/individual/etfs/state-street-energy-select-sector-spdr-etf-xle, and https://www.ssga.com/us/en/individual/etfs/state-street-health-care-select-sector-spdr-etf-xlv. The XLK has a gross annual expense of 0.08% and makes quarterly distributions. The expense is calculated as 86.66 * 0.0008 = 0.069328 per year, or approximately 0.017332 per quarter, and this does not include execution costs. The issuer warns of potential tracking error and secondary-market discounts. If there is an underlying shock, the NAV may decline, and the discount or illiquidity can worsen the realizable fractional RTH exit. However, in orderly markets, tracking can be tight, and there is no current discount shock measured. The issuer benefits from assets and inflows, and the descriptions are of the primary product structure, not independent return forecasts. The fixed ranks and targets are preserved, and single-name, global, or crypto expansion is rejected as it is outside the mandate. A prior concentration study of 3534 was retained, with no repeat of the unchanged simulation.
The proposed investment basket has some potential issues. First, the Technology Select Sector SPDR ETF, or XLK, has 37.20% of its investments in its top 3 holdings, with 43.67% in semiconductors, a price-to-earnings ratio of 26.17, and forecasted growth of 36.25%. The Energy Select Sector SPDR ETF, or XLE, has 35.22% of its investments in its top 2 holdings, with 90.89% in oil and gas, and a price-to-earnings ratio of 12.46. The Health Care Select Sector SPDR ETF, or XLV, has 33.31% of its investments in its top 3 holdings, with 56.67% in pharmaceuticals and biotechnology, and a price-to-earnings ratio of 20.04. These details come from the State Street Global Advisors website. There are some potential negative scenarios, such as disappointing investment demand and earnings for XLK, high earnings for XLE that may not be sustainable, and disappointing drug economics and healthcare cost pressure for XLV. However, there are also some positive possibilities, such as strong earnings delivery, durable energy cash flow, and treatment demand. The issuer may benefit from investments in ETFs, but its estimates and promotional narrative are not independent validation. No new shocking events were found in a search of headlines from September 19. Some headlines about AI cash burn and oil attacks remain unverified and are not being acted upon. These observations are meant to diagnose potential exposure, not to determine a fair value or veto a signal. The fixed rule will be retained, with no discretionary target reset.
The fund manager made two main points about the State Street investment management announcement in November 2020. First, the announcement said that five sector stocks, including XLK, XLY, XLE, XLU, and XLB, would have a 2:1 split, with post-split trading starting on December 5, 2025, and the total value of the market would not change. Second, an audit of the adjusted stock prices found that there were big changes in the prices of XLK, XLE, and XLU, but not in XLB and XLY. The Alpaca stock market data specification says that all adjustments, including splits and dividends, are included in the data. The conclusion is that the missing split units should be normalized before calculating economic returns, and the split should not be seen as a sign of business deterioration or new risk. The split does not change the cash flows, valuation, or sector thesis of the issuer. The FAQ and press release are considered one source from the issuer, not independent confirmation. There is still a gap in the data: the complete dividend reinvestment and index reconciliation have not been measured, and the normalized bar return is a requirement, not a claim of exact official total-return-index identity.
The review is based on two premises. First, the primary holdings of the State Street Technology Select Sector SPDR ETF (XLK), State Street Energy Select Sector SPDR ETF (XLE), and State Street Health Care Select Sector SPDR ETF (XLV) were updated in September 2019, with information available at https://www.ssga.com/us/en/institutional/etfs/state-street-technology-select-sector-spdr-etf-xlk, https://www.ssga.com/us/en/institutional/etfs/state-street-energy-select-sector-spdr-etf-xle, and https://www.ssga.com/us/en/institutional/etfs/state-street-health-care-select-sector-spdr-etf-xlv. The top holdings for these ETFs are as follows: XLK's top three holdings account for 37.20% of the fund, with 43.67% of the fund invested in semiconductors, and the fund's price-to-earnings ratio for the next fiscal year is 26.17, which is based on forecast earnings and a 36.25% growth estimate that was not achieved. XLE's top two holdings account for 35.22% of the fund, with 90.89% of the fund invested in oil and gas. XLV's top three holdings account for 33.31% of the fund, with 37.26% of the fund invested in pharmaceuticals and 19.41% in biotech. Second, the Technical 3379 selection method chooses these holdings based on returns, not valuation. The conclusion is that diversifying by sector does not remove the risk of concentrated earnings. There are strong arguments against investing in these sectors due to potential risks such as slowing chip demand, commodity cash contraction, or drug reimbursement pressure, which could reverse the long-term winners while the Simple Moving Average still lags. These are just scenarios and not based on new events. The different dates of September 2017 and September 2018 are not a contradiction. The review is missing exhaustive constituent filings and does not claim to be a full fundamental valuation. There is no discretionary veto or single-name substitution.
The review is about a potential initial basket with no current holdings. Two premises are considered: the first is based on September 17 issuer holdings and forecast multiples from observations 28531-33, using data from State Street Energy Select Sector SPDR ETF (XLE), State Street Technology Select Sector SPDR ETF (XLK), and State Street Health Care Select Sector SPDR ETF (XLV) websites. The second premise is based on today's price observations 3353, which remain eligible despite weaker market breadth. The strongest bear cases for each ETF are: XLE has a forecast earnings multiple of 12.46x, which may be misleading due to cyclically high earnings, and 35.22% of its holdings are in two issuers, concentrating commodity and capital-allocation exposure. However, integrated operations and supply restraint can cushion demand weakness. XLK has a next-year earnings multiple of 26.17x and 36.25% long-term forecast growth, requiring sustained monetization, and 43.67% of its holdings are in semiconductors, making capex expectations a common shock. However, profits can grow into valuations and relative strength captures that. XLV has a forecast earnings multiple of 20.04x, which is not immune to reimbursement pressure, patent loss, or medical-cost inflation, and 56.67% of its holdings are in pharma and biotech, concentrating product economics. However, durable treatment demand can offset cyclical weakness. No new company-specific adverse events have been verified, and these scenarios are structural, not claims of new policy or earnings revisions. The review is missing constituent unit economics, cash-flow forecasts, and exhaustive new filings, and does not invent fair values. The validity of the review is that concentration can amplify earnings disappointments, but does not establish their timing or probability. The fund issuer directly reports the portfolio but promotes the product, and forecast aggregates originate from analyst estimates, not independent corroboration. Those who may benefit from demand persistence are profitable producers, vendors, drug makers, and their owners, as well as capital raisers from forecast optimism. The conclusion is that bear cases warrant measured exposure and mandate exits, but do not require a new discretionary cash veto.